Antifungal treatment and chronic rhinosinusitis

Devyani Lal, James A. Stankiewicz

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Chronic rhinosinusitis (CRS) is an inflammatory disease with a multifactorial etiology. Antifungal therapy is not routinely used to treat it. However, evidence implicating fungi in some forms of CRS recently has been published. Controversy exists as to whether fungi identified in sinonasal cultures are always pathogenic. Immunologic evidence supporting the role of fungi in the pathogenesis of CRS is also debated. Topical antifungal therapy is more widely used than oral therapy, with amphotericin B irrigation being the most common. Although some studies show benefit from this irrigation, others refute the efficacy. Although oral antifungal agents are used uncommonly, itraconazole is the most commonly used drug. The efficacy of oral itraconazole in CRS has never been assessed in a clinical trial. Given the current evidence, the use of antifungals to treat CRS is controversial and has limited indications.

Original languageEnglish (US)
Pages (from-to)227-231
Number of pages5
JournalCurrent Allergy and Asthma Reports
Issue number3
StatePublished - 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Antifungal treatment and chronic rhinosinusitis'. Together they form a unique fingerprint.

Cite this